| Date Filed | Type | Description |
| 07/26/2021 |
15-12B
| Form 15-12B - Securities registration termination [Section 12(b)]: |
| 07/19/2021 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 07/15/2021 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 07/15/2021 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 07/15/2021 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 07/15/2021 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 07/15/2021 |
POSASR
| Form POSASR - Post-effective Amendment to an automatic shelf registration statement: |
| 07/15/2021 |
POSASR
| Form POSASR - Post-effective Amendment to an automatic shelf registration statement: |
| 07/15/2021 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 07/15/2021 |
8-K
| Resignation/termination of a director |
| 07/15/2021 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 07/15/2021 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 07/15/2021 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
| 06/16/2021 |
SC 14D9
| Form SC 14D9 - Solicitation, recommendation statements: |
| 06/16/2021 |
SC TO-T
| Form SC TO-T - Tender offer statement by Third Party: |
| 06/04/2021 |
SC14D9C
| Form SC14D9C - Written communication relating to third party tender offer: |
| 06/02/2021 |
SC TO-C
| Form SC TO-C - Written communication relating to an issuer or third party: |
| 06/02/2021 |
8-K
| Quarterly results |
| 06/02/2021 |
8-K
| Quarterly results |
| 06/02/2021 |
SC14D9C
| Form SC14D9C - Written communication relating to third party tender offer: |
| 05/10/2021 |
10-Q
| Quarterly Report for the period ended March 31, 2021 |
| 04/27/2021 |
GN
| Constellation Pharmaceuticals to Host Conference Call to Discuss First Quarter 2021 Results |
| 04/23/2021 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/23/2021 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/29/2021 |
CT ORDER
| Form CT ORDER - Confidential treatment order: |
| 03/08/2021 |
5
| GOLDSMITH MARK A (Director) has filed a Form 5 on CONSTELLATION PHARMACEUTICALS INC |
| 02/24/2021 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 02/24/2021 |
GN
| Constellation Pharmaceuticals Announces Fourth-Quarter and Full-Year 2020 Financial Results |
| 02/24/2021 |
10-K
| Annual Report for the period ended December 31, 2020 |
| 02/19/2021 |
GN
| Constellation Pharmaceuticals to Participate in the 10th Annual SVB Leerink Global Healthcare Conference |
| 02/18/2021 |
GN
| Constellation Pharmaceuticals to Host Conference Call to Discuss Fourth Quarter 2020 Results |
| 02/16/2021 |
SC 13G/A
| THIRD ROCK VENTURES LP reports a 0.3% stake in Constellation Pharmaceuticals, Inc. |
| 02/16/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/16/2021 |
SC 13G/A
| Bain Capital Life Sciences Fund, L.P. reports a 2.7% stake in Constellation Pharmaceuticals, Inc. |
|